CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV

INTRODUCTION: The chemokine receptor CCR5 has garnered significant attention in recent years as a target to treat HIV infection largely due to the approval and success of the drug Maraviroc. The side effects and inefficiencies with other first generation agents led to failed clinical trials, prompti...

Full description

Saved in:
Bibliographic Details
Published in:Expert Opin Investig Drugs
Main Authors: Kim, Michelle B., Giesler, Kyle E., Tahirovic, Yesim A., Truax, Valarie M., Liotta, Dennis C., Wilson, Lawrence J.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5776690/
https://ncbi.nlm.nih.gov/pubmed/27791451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2016.1254615
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items